SG Americas Securities LLC Boosts Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

SG Americas Securities LLC grew its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 46.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,419 shares of the company’s stock after acquiring an additional 16,856 shares during the quarter. SG Americas Securities LLC’s holdings in Wave Life Sciences were worth $661,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after purchasing an additional 1,905 shares during the period. Point72 DIFC Ltd bought a new position in shares of Wave Life Sciences in the third quarter worth about $98,000. Hsbc Holdings PLC purchased a new position in Wave Life Sciences in the 2nd quarter worth about $104,000. Finally, Orion Portfolio Solutions LLC bought a new stake in Wave Life Sciences during the 3rd quarter valued at about $123,000. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Stock Performance

Shares of Wave Life Sciences stock opened at $12.06 on Friday. The company has a market capitalization of $1.84 billion, a PE ratio of -10.86 and a beta of -1.07. The company has a 50-day simple moving average of $13.16 and a two-hundred day simple moving average of $10.32. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $16.74.

Insider Transactions at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 51,234 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares of the company’s stock, valued at approximately $3,112,466.32. This trade represents a 19.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chris Francis sold 36,000 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 137,234 shares of company stock valued at $2,059,671 in the last 90 days. Insiders own 29.10% of the company’s stock.

Wall Street Analyst Weigh In

WVE has been the topic of a number of research reports. Leerink Partners raised their target price on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. JPMorgan Chase & Co. raised their price objective on Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. Truist Financial upped their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. Mizuho raised their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Finally, StockNews.com lowered shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.22.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.